However, the development of anti-claudin therapies has opened a horizon of hope for advanced GC patients, and numerous ongoing trials are exploring novel and promising targets such as FGFR and MET, new antiangiogenic, immunotherapeutic, and anti-HER2 approaches, as well as innovative drug delivery systems [8,9,10,11,12]. This evidence concerns the gene ERBB2 and gastric cancer.